Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections

Authors

Victoria Gavaghan, Advocate Aurora HealthFollow
Jessica L. Miller, Advocate Aurora HealthFollow
Jennifer Dela-Pena, Department of Pharmacy, Cleveland Clinic, Cleveland, OH, USA.Follow

Recommended Citation

Gavaghan V, Miller JL, Dela-Pena J. Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections. Infection. 2023;51(2):475-482. doi:10.1007/s15010-022-01933-5

Affiliations

Advocate Lutheran General Hospital

Abstract

Purpose: This case series describes real-world utilization of cefiderocol and associated clinical outcomes in the setting of carbapenem-resistant Gram-negative bacterial infections.

Methods: Adult hospitalized patients administered at least 5 days of cefiderocol as definitive treatment from October 1, 2020 to September 16, 2021 were included in this retrospective cohort analysis. The primary outcome was clinical success defined as a composite of 30 day survival, resolution of infection, and absence of 30 day recurrence of the same organism.

Results: Among 24 patients, pneumonia (19, 79%) was the most common source of infection with Acinetobacter baumannii (14, 58%) and P. aeruginosa (10, 42%) as the predominant organisms isolated. Cefiderocol monotherapy was used as definitive treatment in 16 (67%) patients. Eleven patients (46%) met clinical success. Thirty-day mortality occurred in ten (42%) patients while seven (29%) patients had recurrence of infection. Thirteen out of 21 total isolates (62%) tested for susceptibility were deemed susceptible. Of the 16 patients with available susceptibility, 9 (56%) had an infection where all isolated organisms were susceptible to cefiderocol.

Conclusions: Our results provide additional insight into the in vivo activity of cefiderocol. Cefiderocol remains a salvage option for carbapenem-resistant Gram-negative organisms.

Document Type

Article

PubMed ID

36201152